Latest News and Press Releases

Ketabon, a JV between HMNC and Develco, shared new post hoc Phase 2 data for oral ketamine (KET01) in treatment-resistant depression (TRD)

HMNC presented data showing distinct nelivaptan response patterns, supporting its precision, genetics-guided approach to treating depression.

BH-200 (nelivaptan) achieved clinically meaningful reduction in depressive symptoms across the full study population (Difference between BH-200 and placebo in HAM-D17 change from baseline at Week 8:...

Study Initiation Marks Key Milestone in Advancing Precision Psychiatry Treatment for Major Depressive Disorder Topline Results Anticipated in the First Half of 2026 MUNICH, Germany and SOUTH SAN...

MUNICH, Jan. 10, 2025 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC”), a clinical-stage precision psychiatry biopharma company pioneering personalized treatments powered by predictive companion...

MUNICH, Dec. 11, 2024 (GLOBE NEWSWIRE) -- HMNC Brain Health, a clinical-stage precision psychiatry biopharma company, pioneering the development of personalized therapies powered by predictive...

MUNICH, Oct. 31, 2024 (GLOBE NEWSWIRE) -- HMNC Brain Health (or “HMNC”), a clinical-stage precision psychiatry biopharma company, pioneering the development of personalized therapies powered by...

MUNICH, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Ketabon GmbH (“Ketabon” or “the Company”), a joint venture between HMNC Brain Health and Develco Pharma, announced today that the Company will present two...

MUNICH, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- Ketabon GmbH (“Ketabon” or “the Company”), a joint venture between HMNC Brain Health and Develco Pharma, announced today the Company will present...

Results Suggest Formulation Potentially Suitable for At-Home Administration Ketabon Also Releases In-Depth Data from Phase 2 KET01 Trial  MUNICH, Germany, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Ketabon...